Andere talen DermTech, Inc.

Aandelen

DMTK

US24984K1051

Geschatte realtime Cboe BZX Andere beurzen 18:01:51 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,603 ^USD	+3,01%		-4,52%	-64,86%

19/04	DERMTECH, INC. : Lake Street verlaagt advies naar Neutraal	ZM
19/04	DERMTECH, INC. : BTIG herziet opinie en gaat over naar Neutraal	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

North American Morning Briefing : Stock Futures -2-	22/04
DermTech Explores Strategic Alternatives to Boost Shareholder Value, Lays Off 100 Employees in Restructuring Plan	18/04
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	18/04
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	18/04
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	11/03
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	08/03
DermTech : 2023 Q4 Transcript	01/03
DermTech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
DermTech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (DMTK) DERMTECH Reports Q4 Revenue $3.9M, vs. Street Est of $4.03M	29/02
DermTech Reports Fourth-Quarter 2023 Financial Results	29/02
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results	13/02
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations	31/01
Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer	31/01
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test across All Skin Types	19/01
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types	18/01
DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test Across All Skin Types	18/01
DERMTECH SIMPLIFIES THE DERMTECH MELANOMA TEST BY DISCONTINUING THE OPTIONAL TERT ADD-ON ASSAY	17/01
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay	16/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen DermTech, Inc.

Aandelen

DMTK

US24984K1051

Andere talen

Filters